Brown University — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications7liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
RasagilineWhile Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkinson's disease. These deficits are often subtle and do not rise to the level of impairment necessary for a diagnosis of dementia; however these deficits are discernable with neuropsychological testing and may produce subjective complaints of cognitive decline and mild functional difficulties in some patients. The traditional pharmacological interventions for Parkinson's disease have focused on controlling and alleviating motor symptoms with levodopa and dopamine agonists. However, these medications treat the symptoms of PD, but do not alter the course or progression of the underlying disorder. In contrast, rasagiline, an MAO-B inhibitor, has recently shown benefits consistent with a possible disease-modifying effect. Given the positive and intriguing findings seen with treatment with rasagiline, the investigators propose to study the effects of this medication on cognition in patients with mild to moderate stage Parkinson's disease. Hypotheses: 1. Rasagiline will improve cognitive function, as measured by performance on neuropsychological tests in PD patients who do not suffer from dementia. 2. Rasagiline will not negatively affect neuropsychiatric functioning.	Parkinson	Phase 4	Ralentissement de la progression + Traitement symptomatique	United States	À vérifier
RasagilineWhile Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkinson's disease. These deficits are often subtle and do not rise to the level of impairment necessary for a diagnosis of dementia; however these deficits are discernable with neuropsychological testing and may produce subjective complaints of cognitive decline and mild functional difficulties in some patients. The traditional pharmacological interventions for Parkinson's disease have focused on controlling and alleviating motor symptoms with levodopa and dopamine agonists. However, these medications treat the symptoms of PD, but do not alter the course or progression of the underlying disorder. In contrast, rasagiline, an MAO-B inhibitor, has recently shown benefits consistent with a possible disease-modifying effect. Given the positive and intriguing findings seen with treatment with rasagiline, the investigators propose to study the effects of this medication on cognition in patients with mild to moderate stage Parkinson's disease. Hypotheses: 1. Rasagiline will improve cognitive function, as measured by performance on neuropsychological tests in PD patients who do not suffer from dementia. 2. Rasagiline will not negatively affect neuropsychiatric functioning.	Parkinson	Phase 4	Ralentissement de la progression + Traitement symptomatique	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Rasagiline	Parkinson	Phase 4	NCT01382342	The Effect of Rasagiline on Cognition in Parkinson's Disease	COMPLETED

Publications

7

Molécule	Indication / population	Titre	Journal	Date
Rasagiline		Exploiting the Danio rerio model and bioinformatics to explore the effects and molecular networks of Parkinson's disease drugs in human melanoma.	European journal of cell biology
Rasagiline		Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson's disease.	Journal of enzyme inhibition and medicinal chemistry
Rasagiline		An In Vivo Single-Vesicle Electrochemistry Enables Monitoring Vesicular Dopamine Dynamics and Pharmacological Rescue.	Angewandte Chemie (International ed. in English)
Rasagiline		Sex-Specific Association of Rasagiline with Motor Progression in -Associated Parkinson's Disease.	Life (Basel, Switzerland)
Rasagiline		Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms.	EBioMedicine
Rasagiline		Correction: Case Report: A possible novel adult-onset, progressive MAO-A hypofunction.	Frontiers in neuroscience
Rasagiline		A successful switch from rasagiline to safinamide in a 49-year-old female with early-onset Parkinson's disease: a case report and review of literature.	Naunyn-Schmiedeberg's archives of pharmacology